Skip to search formSkip to main content

volitinib

Known as: SAVOLITINIB 
An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Volitinib selectively binds to and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Opinion statementNext-generation sequencing (NGS) of circulating tumor DNA (ctDNA) is a novel technology that can complement… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2018
2018
BackgroundPatient-derived xenograft (PDX) models with definite molecular signature are attractive preclinical models for… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic options. PRCC may involve… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2016
2016
Amplified and/or mutated MET can act as both a primary oncogenic driver and as a promoter of tyrosine kinase inhibitor (TKI… Expand
Is this relevant?
2015
2015
PURPOSE To investigate the incidence of cMET gene copy number changes and protein overexpression in Chinese gastric cancer (GC… Expand
Is this relevant?
2015
2015
PURPOSE Papillary renal cell carcinoma (PRCC) is the second most common cancer of the kidney and carries a poor prognosis for… Expand
Is this relevant?
2014
2014
11111 Background: Volitinib is a selective oral small molecule inhibitor of cMet kinase with potent in vivo inhibitory effects on… Expand
Is this relevant?
2014
2014
HGF/c-Met signaling has been implicated in human cancers. Herein we describe the invention of a series of novel triazolopyrazine… Expand
Is this relevant?
2013
2013
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC It is well recognized that non-small cell lung… Expand
Is this relevant?
2013
2013
Volitinib is a novel selective cMet inhibitor. This study is to evaluate its preclinical ADME/PK profile. Volitinib has high… Expand
Is this relevant?